Open AccessManagement of primary vasculitides with biologic and novel small molecule medications
Author(s) -
Naomi SerlingBoyd,
Zachary S Wallace
Publication year - 2021
Publication title -
current opinion in rheumatology/current opinion in rheumatology, with evaluated medline
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.452
H-Index - 112
eISSN - 1080-8175
pISSN - 1040-8711
DOI - 10.1097/bor.0000000000000756
Subject(s) - medicine , rituximab , tocilizumab , giant cell arteritis , vasculitis , microscopic polyangiitis , glucocorticoid , granulomatosis with polyangiitis , prednisolone , immunology , regimen , proteinase 3 , systemic vasculitis , dermatology , disease , antibody
Vasculitides can affect small, medium and/or large vessels, leading to end-organ damage, decreased quality of life and death. Glucocorticoids remain the backbone of treatment for systemic vasculitis but are associated with numerous toxicities. In recent years, the efficacy of glucocorticoid-sparing biologic and novel small molecule therapies has been demonstrated.